Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

[1]  I. Lowy,et al.  Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[2]  Jurgen Müller,et al.  BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells , 2012, International journal of cancer.

[3]  T. Fojo,et al.  Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. , 2010, The oncologist.

[4]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[5]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[6]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Steinberg,et al.  Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer , 2010, Cancer Immunology, Immunotherapy.

[8]  P. Kantoff,et al.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[10]  J. Waisman,et al.  Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. O’Day,et al.  Phase I/II study of ipilimumab for patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Dorff,et al.  Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC) , 2008 .

[13]  S. Steinberg,et al.  Clinical safety of a viral vector based prostate cancer vaccine strategy. , 2007, The Journal of urology.

[14]  J. Allison,et al.  A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? , 2007, Novartis Foundation symposium.

[15]  J. Schlom,et al.  The Human T-Box Mesodermal Transcription Factor Brachyury Is a Candidate Target for T-Cell–Mediated Cancer Immunotherapy , 2007, Clinical Cancer Research.

[16]  E. Small,et al.  A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.

[17]  P. Schellhammer,et al.  Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Small,et al.  Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. , 2006, The Journal of urology.

[19]  J. Schlom,et al.  Multiple Costimulatory Modalities Enhance CTL Avidity , 2005, The Journal of Immunology.

[20]  C. N. Coleman,et al.  Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer , 2005, Clinical Cancer Research.

[21]  J. Schlom,et al.  Induction of an Antigen Cascade by Diversified Subcutaneous/Intratumoral Vaccination Is Associated with Antitumor Responses , 2005, Clinical Cancer Research.

[22]  S. Groshen,et al.  Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[25]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[26]  J. Schlom,et al.  The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[28]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[29]  Levine,et al.  MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage. , 1999, Molecular urology.